Nonetheless, the advent of novel antibody-drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd), which deliver cytotoxic agents to cells with low HER2 levels, has opened a new therapeutic option for this substantial BC patient population [60]. The gene discussed is ERBB2; the disease is breast cancer.